IbogaBaseThe Iboga Evidence Base
Clinical boundary Schedule I in the U.S. Serious cardiac risk Not FDA-approved No dosing or referrals Schedule I · cardiac risk Not FDA-approved · no referrals

Clinical reference

Clinician brief

LAST REVIEWED 2026-05-18 · 346 SOURCES · 0 CORRECTIONS

A concise clinical orientation to evidence, safety, interaction categories, adverse-event themes, and comparison with approved treatments.

Start with risk

Ibogaine is not FDA-approved as a treatment in the United States. Published safety discussion repeatedly centers QT/QTc, bradycardia, rhythm events, electrolyte context, medication interactions, polysubstance exposure, psychiatric exclusions, and emergency readiness.

Cardiac frame

Read benefit claims alongside QT/QTc, rhythm risk, bradycardia, electrolyte abnormalities, dehydration, withdrawal physiology, and emergency response capacity.

Interaction frame

Medication review matters for QT-prolonging drugs, serotonergic drugs, stimulants, opioids, alcohol, benzodiazepines, antipsychotics, antidepressants, and CYP2D6-related questions.

Evidence frame

Separate open-label observational studies, case reports, trial registries, reviews, preclinical mechanisms, media claims, and company releases before drawing clinical conclusions.

Evidence by condition

Condition Evidence Setting What's not proven
Opioid use disorder Evidence: Moderateearly human and observational Observational detoxification reports, follow-up studies, and registered oral Ibogaine withdrawal research. Ibogaine is not proven to cure opioid addiction.
Alcohol use disorder Evidence: Moderateinvestigational FDA allowed an early phase U.S. Noribogaine hydrochloride study to proceed after an IND submission in April 2026. Noribogaine is not FDA-approved for alcohol use disorder.
Traumatic brain injury Evidence: Moderatenotable open label human signal A 30-person veteran prospective observational study and later neurophysiology work drew attention and require side-by-side design-limit explanation. Ibogaine is not proven as a general TBI treatment.
PTSD and trauma symptoms Evidence: Moderatesecondary outcomes and observational PTSD-related signals often appear within veteran or substance-use populations rather than standalone PTSD trials. Ibogaine is not proven as a PTSD treatment.
Depression and mood symptoms Evidence: Moderatesecondary outcomes and small reports Mood improvements appear in some Ibogaine-related observational and veteran studies, usually as secondary outcomes. Ibogaine is not proven as a depression treatment.
Parkinson's disease Evidence: Lowcase report watchlist A 2026 peer-reviewed case report describes one patient treated with low-dose Ibogaine hydrochloride over 80 days using validated Parkinson's instruments. Ibogaine is not proven as a Parkinson's treatment.
Withdrawal Evidence: Moderateearly human signal by context Withdrawal and craving findings appear in OUD studies, observational detoxification reports, and substance-use reviews. Craving reduction or withdrawal relief is not the same as a cure.
Cravings Evidence: Moderateearly human signal by context Withdrawal and craving findings appear in OUD studies, observational detoxification reports, and substance-use reviews. Craving reduction or withdrawal relief is not the same as a cure.

Approved-treatment context

Ibogaine comparisons with buprenorphine, methadone, and naltrexone should distinguish approved medications from investigational or unapproved interventions. A policy opening, clinic testimonial, podcast interview, or company release is not a substitute for controlled evidence, safety monitoring, and regulatory review.